Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Prognostic impact of angiographic findings, procedural success, and timing of percutaneous coronary intervention in cardiogenic shock

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Anabolic-Androgenic Steroid Abuse Impairs Fibrin Clot Lysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: Cardiac cachexia is a wasting syndrome characterized by chronic inflammation and high mortality. Fibroblast growth factor 21 (FGF-21) and monocyte chemoattractant protein 1 (MCP-1) are associated with cardiovascular disease and systemic inflammation. We investigated FGF-21 and MCP-1 in relations to cardiac function, inflammation, and wasting in patients with heart failure with reduced ejection fraction (HFrEF) and cardiac cachexia.

METHODS AND RESULTS: Plasma FGF-21 and MCP-1 were measured in a cross-sectional study among the three study groups: 19 patients with HFrEF with cardiac cachexia, 19 patients with HFrEF without cachexia, and 19 patients with ischaemic heart disease and preserved ejection fraction. Patients with HFrEF and cardiac cachexia displayed higher FGF-21 levels median (inter quantile range) 381 (232-577) pg/mL than patients with HFrEF without cachexia 224 (179-309) pg/mL and ischaemic heart disease patients 221 (156-308) pg/mL (P = 0.0496). No difference in MCP-1 levels were found among the groups (P = 0.345). In a multivariable regression analysis, FGF-21 (logarithm 2) was independently associated with interleukin 6 (logarithm 2) (P = 0.015) and lower muscle mass (P = 0.043), while no relation with N-terminal pro-hormone brain natriuretic peptide was observed.

CONCLUSIONS: Fibroblast growth factor 21 (FGF-21) levels were elevated in patients with HFrEF and cardiac cachexia, which could be mediated by increased inflammation and muscle wasting rather than impaired cardiac function.

Original languageEnglish
JournalESC Heart Failure
Volume6
Issue number5
Pages (from-to)983-991
Number of pages9
ISSN2055-5822
DOIs
Publication statusPublished - Oct 2019

ID: 59042118